Loading...

Robert Charles Seeger, MD

Title(s)Professor of Pediatrics
Phone+1 323 361 5618
vCardDownload vCard
    Other Positions
    Title(s)Section Head for Research in the Division of HemOncBMT


    Collapse Biography 
    Collapse Awards and Honors
    University of Southern California School2011Mellon Mentoring Award
    Willamette University2008Distinguished Alumni Citation
    2001H. Russell Smith Award for Innovation in Pediatric Biomedical Research

    Collapse Overview 
    Collapse Overview
    Dr. Seeger is Professor of Pediatrics in the Keck School of Medicine, Director of Cancer Research Program of the Saban Research Institute, and Division Head for Basic and Translational Research of the Center for Cancer and Blood Diseases at CHLA. Dr. Seeger obtained MD and MS degrees from the University of Oregon School of Medicine, Pediatric training at the University of Minnesota, and research training at the NIH and University College London. Before joining USC in 1989 as a Professor of Pediatrics, he was Professor of Pediatrics at the UCLA School of Medicine.

    He is a well-funded investigator and currently is the Principal Investigator of a PPG, an R01, an R33, and two U10s. Dr. Seeger’s therapeutic research deals with immunotherapy strategies that seek to maximize natural killer (NK) cell activity with tumor cell targeting antibodies and with agents that modify the tumor microenvironment milieu to minimize NK suppressive effects of monocytes/macrophages producing IL-6 and TGFß1. His biomarker research, in collaboration with Dr. Shahab Asgharzadeh, has resulted in a 14-gene expression signature (TaqMan® Low Density Array, TLDA) that predicts outcome for children with high-risk metastatic neuroblastoma. He also has developed a second TLDA assay that quantifies expression of 5 neuroblastoma genes in bone marrow and blood with the ability to detect 1 tumor cell/million normal cells. This assay is proving useful for monitoring response and predicting outcome.

    Finally, in his role as Principal Investigator of and NCI-funded Neuroblastoma PPG, he Co-Chairs the Scientific Review Committee of the New Approaches to Neuroblastoma Therapy consortium (NANT, see www.nant.org), which sets directions and reviews clinical trial proposals. The NANT is an early-phase clinical trials consortium of 15 institutions in North America that tests new treatments, biomarkers, and imaging for children with refractory or recurrent neuroblastoma. Thus, his expertise includes pre-clinical immunotherapy, biomarker development and application, and early phase clinical trials.

    Collapse Research 
    Collapse Research Activities and Funding
    Discovering and Exploiting Mechanisms of Neuroblastoma Therapy Resistance
    NIH/NCI P01CA217959Sep 18, 2017 - Aug 31, 2022
    Role: Principal Investigator
    Molecular Diagnostics for Risk Stratification and Monitoring of Neuroblastoma
    NIH/NCI R01CA182633Mar 4, 2014 - Feb 28, 2017
    Role: Co-Principal Investigator
    Gene Expression of Neuroblastoma and Normal Cells in Bone Marrow Predicts Outcome
    NIH/NCI R33CA152809Sep 1, 2010 - Aug 31, 2013
    Role: Principal Investigator
    Biology and Therapy of High Risk Neuroblastoma
    NIH/NCI P01CA081403Jul 6, 2000 - May 31, 2015
    Role: Principal Investigator
    Clinical Correlative Studies of Neuroblastoma
    NIH/NCI R01CA060104Aug 1, 1993 - Jul 31, 2012
    Role: Principal Investigator
    CLINICAL CORRELATIVE STUDIES OF NEUROBLASTOMA
    NIH/NCI U01CA060104Aug 1, 1993 - Jan 31, 1998
    Role: Principal Investigator
    IMMUNOCYTOLOGY OF MARROW METASTASES IN NEUROBLASTOMA
    NIH/NCI R03CA053329Sep 30, 1990 - Sep 29, 1992
    Role: Principal Investigator
    HUMAN NEUROBLASTOMA ANTIGENS
    NIH/NCI R01CA022794Feb 1, 1978 - Mar 31, 2003
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Websites
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Wu HW, Sheard MA, Malvar J, Fernandez GE, DeClerck YA, Blavier L, Shimada H, Theuer CP, Sposto R, Seeger RC. Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells. Clin Cancer Res. 2019 May 08. PMID: 31068371.
      View in: PubMed
    2. Wu CH, Li J, Li L, Sun J, Fabbri M, Wayne AS, Seeger RC, Jong AY. Extracellular vesicles derived from natural killer cells use multiple cytotoxic proteins and killing mechanisms to target cancer cells. J Extracell Vesicles. 2019; 8(1):1588538. PMID: 30891164.
      View in: PubMed
    3. Neviani P, Wise PM, Murtadha M, Liu CW, Wu CH, Jong AY, Seeger RC, Fabbri M. Natural Killer-Derived Exosomal miR-186 Inhibits Neuroblastoma Growth and Immune Escape Mechanisms. Cancer Res. 2019 Mar 15; 79(6):1151-1164. PMID: 30541743.
      View in: PubMed
    4. Barry WE, Jackson JR, Asuelime GE, Wu HW, Sun J, Wan Z, Malvar J, Sheard MA, Wang L, Seeger RC, Kim ES. Activated Natural Killer Cells in Combination with Anti-GD2 Antibody Dinutuximab Improve Survival of Mice after Surgical Resection of Primary Neuroblastoma. Clin Cancer Res. 2019 Jan 01; 25(1):325-333. PMID: 30232225.
      View in: PubMed
    5. Ozkaynak MF, Gilman AL, London WB, Naranjo A, Diccianni MB, Tenney SC, Smith M, Messer KS, Seeger R, Reynolds CP, Smith LM, Shulkin BL, Parisi M, Maris JM, Park JR, Sondel PM, Yu AL. Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931. Front Immunol. 2018; 9:1641. PMID: 30046297.
      View in: PubMed
    6. Ozkaynak MF, Gilman AL, London WB, Naranjo A, Diccianni MB, Tenney SC, Smith M, Messer KS, Seeger R, Reynolds CP, Smith LM, Shulkin BL, Parisi M, Maris JM, Park JR, Sondel PM, Yu AL. A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931. Front Immunol. 2018; 9:1355. PMID: 29967609.
      View in: PubMed
    7. Wei JS, Kuznetsov IB, Zhang S, Song YK, Asgharzadeh S, Sindiri S, Wen X, Patidar R, Najaraj S, Walton A, Auvil JMG, Gerhard DS, Yuksel A, Catchpoole D, Hewitt SM, Sondel PM, Seeger R, Maris JM, Khan J. Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk MYCN-Not-Amplified Human Neuroblastoma. Clin Cancer Res. 2018 Nov 15; 24(22):5673-5684. PMID: 29784674.
      View in: PubMed
    8. Webb MW, Sun J, Sheard MA, Liu WY, Wu HW, Jackson JR, Malvar J, Sposto R, Daniel D, Seeger RC. Colony stimulating factor 1 receptor blockade improves the efficacy of chemotherapy against human neuroblastoma in the absence of T lymphocytes. Int J Cancer. 2018 09 15; 143(6):1483-1493. PMID: 29665011.
      View in: PubMed
    9. Rajbhandari P, Lopez G, Capdevila C, Salvatori B, Yu J, Rodriguez-Barrueco R, Martinez D, Yarmarkovich M, Weichert-Leahey N, Abraham BJ, Alvarez MJ, Iyer A, Harenza JL, Oldridge D, De Preter K, Koster J, Asgharzadeh S, Seeger RC, Wei JS, Khan J, Vandesompele J, Mestdagh P, Versteeg R, Look AT, Young RA, Iavarone A, Lasorella A, Silva JM, Maris JM, Califano A. Cross-Cohort Analysis Identifies a TEAD4-MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma. Cancer Discov. 2018 May; 8(5):582-599. PMID: 29510988.
      View in: PubMed
    10. Robison NJ, Yeo KK, Berliner AP, Malvar J, Sheard MA, Margol AS, Seeger RC, Rushing T, Finlay JL, Sposto R, Dhall G. Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors. J Neurooncol. 2018 May; 138(1):199-207. PMID: 29427149.
      View in: PubMed
    11. Niemas-Teshiba R, Matsuno R, Wang LL, Tang XX, Chiu B, Zeki J, Coburn J, Ornell K, Naranjo A, Van Ryn C, London WB, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Seeger RC, Asgharzadeh S, Ikegaki N, Shimada H. MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology group. Oncotarget. 2018 Jan 19; 9(5):6416-6432. PMID: 29464082.
      View in: PubMed
    12. Wen C, Seeger RC, Fabbri M, Wang L, Wayne AS, Jong AY. Biological roles and potential applications of immune cell-derived extracellular vesicles. J Extracell Vesicles. 2017; 6(1):1400370. PMID: 29209467.
      View in: PubMed
    13. Borriello L, Nakata R, Sheard MA, Fernandez GE, Sposto R, Malvar J, Blavier L, Shimada H, Asgharzadeh S, Seeger RC, DeClerck YA. Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells. Cancer Res. 2017 09 15; 77(18):5142-5157. PMID: 28687621.
      View in: PubMed
    14. Marachelian A, Villablanca JG, Liu CW, Liu B, Goodarzian F, Lai HA, Shimada H, Tran HC, Parra JA, Gallego R, Bedrossian N, Young S, Czarnecki S, Kennedy R, Weiss BD, Goldsmith K, Granger M, Matthay KK, Groshen S, Asgharzadeh S, Sposto R, Seeger RC. Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis. Clin Cancer Res. 2017 Sep 15; 23(18):5374-5383. PMID: 28559462.
      View in: PubMed
    15. Jong AY, Wu CH, Li J, Sun J, Fabbri M, Wayne AS, Seeger RC. Large-scale isolation and cytotoxicity of extracellular vesicles derived from activated human natural killer cells. J Extracell Vesicles. 2017; 6(1):1294368. PMID: 28326171.
      View in: PubMed
    16. Burchill SA, Beiske K, Shimada H, Ambros PF, Seeger R, Tytgat GA, Brock PR, Haber M, Park JR, Berthold F. Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma on behalf of the International Neuroblastoma Response Criteria Bone Marrow Working Group. Cancer. 2017 Apr 01; 123(7):1095-1105. PMID: 27984660.
      View in: PubMed
    17. Gutova M, Goldstein L, Metz M, Hovsepyan A, Tsurkan LG, Tirughana R, Tsaturyan L, Annala AJ, Synold TW, Wan Z, Seeger R, Anderson C, Moats RA, Potter PM, Aboody KS. Optimization of a Neural Stem-Cell-Mediated Carboxylesterase/Irinotecan Gene Therapy for Metastatic Neuroblastoma. Mol Ther Oncolytics. 2017 Mar 17; 4:67-76. PMID: 28345025.
      View in: PubMed
    18. Erdreich-Epstein A, Singh AR, Joshi S, Vega FM, Guo P, Xu J, Groshen S, Ye W, Millard M, Campan M, Morales G, Garlich JR, Laird PW, Seeger RC, Shimada H, Durden DL. Association of high microvessel avß3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126. Oncotarget. 2017 Aug 08; 8(32):52193-52210. PMID: 28881723.
      View in: PubMed
    19. Tran HC, Wan Z, Sheard MA, Sun J, Jackson JR, Malvar J, Xu Y, Wang L, Sposto R, Kim ES, Asgharzadeh S, Seeger RC. TGFßR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells. Clin Cancer Res. 2017 Feb 01; 23(3):804-813. PMID: 27756784.
      View in: PubMed
    20. Jackson JR, Kim Y, Seeger RC, Kim ES. A novel minimal residual disease model of neuroblastoma in mice. J Pediatr Surg. 2016 Jun; 51(6):991-4. PMID: 26995512.
      View in: PubMed
    21. Zhang S, Wei JS, Li SQ, Badgett TC, Song YK, Agarwal S, Coarfa C, Tolman C, Hurd L, Liao H, He J, Wen X, Liu Z, Thiele CJ, Westermann F, Asgharzadeh S, Seeger RC, Maris JM, Guidry Auvil JM, Smith MA, Kolaczyk ED, Shohet J, Khan J. MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma. Cancer Lett. 2016 Feb 28; 371(2):214-24. PMID: 26683771.
      View in: PubMed
    22. Borriello L, Seeger RC, Asgharzadeh S, DeClerck YA. More than the genes, the tumor microenvironment in neuroblastoma. Cancer Lett. 2016 09 28; 380(1):304-14. PMID: 26597947.
      View in: PubMed
    23. Schnepp RW, Khurana P, Attiyeh EF, Raman P, Chodosh SE, Oldridge DA, Gagliardi ME, Conkrite KL, Asgharzadeh S, Seeger RC, Madison BB, Rustgi AK, Maris JM, Diskin SJ. A LIN28B-RAN-AURKA Signaling Network Promotes Neuroblastoma Tumorigenesis. Cancer Cell. 2015 Nov 09; 28(5):599-609. PMID: 26481147.
      View in: PubMed
    24. Anderson CP, Matthay KK, Perentesis JP, Neglia JP, Bailey HH, Villablanca JG, Groshen S, Hasenauer B, Maris JM, Seeger RC, Reynolds CP. Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma. Pediatr Blood Cancer. 2015 Oct; 62(10):1739-46. PMID: 26153194.
      View in: PubMed
    25. Russell MR, Penikis A, Oldridge DA, Alvarez-Dominguez JR, McDaniel L, Diamond M, Padovan O, Raman P, Li Y, Wei JS, Zhang S, Gnanchandran J, Seeger R, Asgharzadeh S, Khan J, Diskin SJ, Maris JM, Cole KA. CASC15-S Is a Tumor Suppressor lncRNA at the 6p22 Neuroblastoma Susceptibility Locus. Cancer Res. 2015 Aug 01; 75(15):3155-66. PMID: 26100672; PMCID: PMC4526355.
    26. Wang LL, Teshiba R, Ikegaki N, Tang XX, Naranjo A, London WB, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Seeger RC, Asgharzadeh S, Shimada H. Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study. Br J Cancer. 2015 Jun 30; 113(1):57-63. PMID: 26035700.
      View in: PubMed
    27. Challagundla KB, Wise PM, Neviani P, Chava H, Murtadha M, Xu T, Kennedy R, Ivan C, Zhang X, Vannini I, Fanini F, Amadori D, Calin GA, Hadjidaniel M, Shimada H, Jong A, Seeger RC, Asgharzadeh S, Goldkorn A, Fabbri M. Exosome-mediated transfer of microRNAs within the tumor microenvironment and neuroblastoma resistance to chemotherapy. J Natl Cancer Inst. 2015 Jul; 107(7). PMID: 25972604.
      View in: PubMed
    28. Oberthuer A, Juraeva D, Hero B, Volland R, Sterz C, Schmidt R, Faldum A, Kahlert Y, Engesser A, Asgharzadeh S, Seeger R, Ohira M, Nakagawara A, Scaruffi P, Tonini GP, Janoueix-Lerosey I, Delattre O, Schleiermacher G, Vandesompele J, Speleman F, Noguera R, Piqueras M, Bénard J, Valent A, Avigad S, Yaniv I, Grundy RG, Ortmann M, Shao C, Schwab M, Eils R, Simon T, Theissen J, Berthold F, Westermann F, Brors B, Fischer M. Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers. Clin Cancer Res. 2015 Apr 15; 21(8):1904-15. PMID: 25231397.
      View in: PubMed
    29. Teshiba R, Kawano S, Wang LL, He L, Naranjo A, London WB, Seeger RC, Gastier-Foster JM, Look AT, Hogarty MD, Cohn SL, Maris JM, Park JR, Shimada H. Age-dependent prognostic effect by Mitosis-Karyorrhexis Index in neuroblastoma: a report from the Children's Oncology Group. Pediatr Dev Pathol. 2014 Nov-Dec; 17(6):441-9. PMID: 25207821.
      View in: PubMed
    30. Gustafson WC, Meyerowitz JG, Nekritz EA, Chen J, Benes C, Charron E, Simonds EF, Seeger R, Matthay KK, Hertz NT, Eilers M, Shokat KM, Weiss WA. Drugging MYCN through an allosteric transition in Aurora kinase A. Cancer Cell. 2014 Sep 08; 26(3):414-427. PMID: 25175806.
      View in: PubMed
    31. Fei F, Lim M, George AA, Kirzner J, Lee D, Seeger R, Groffen J, Abdel-Azim H, Heisterkamp N. Cytotoxicity of CD56-positive lymphocytes against autologous B-cell precursor acute lymphoblastic leukemia cells. Leukemia. 2015 Apr; 29(4):788-97. PMID: 25134458.
      View in: PubMed
    32. Xu Y, Sun J, Sheard MA, Tran HC, Wan Z, Liu WY, Asgharzadeh S, Sposto R, Wu HW, Seeger RC. Lenalidomide overcomes suppression of human natural killer cell anti-tumor functions by neuroblastoma microenvironment-associated IL-6 and TGFß1. Cancer Immunol Immunother. 2013 Oct; 62(10):1637-48. PMID: 23982484.
      View in: PubMed
    33. Wang LL, Suganuma R, Ikegaki N, Tang X, Naranjo A, McGrady P, London WB, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Seeger RC, Shimada H. Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology Group. Cancer. 2013 Oct 15; 119(20):3718-26. PMID: 23901000.
      View in: PubMed
    34. Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA, Haas-Kogan DA, Laquaglia MP, Yu AL, Diller L, Buxton A, Park JR, Cohn SL, Maris JM, Reynolds CP, Villablanca JG. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol. 2013 Sep; 14(10):999-1008. PMID: 23890779; PMCID: PMC3963485.
    35. Sheard MA, Asgharzadeh S, Liu Y, Lin TY, Wu HW, Ji L, Groshen S, Lee DA, Seeger RC. Membrane-bound TRAIL supplements natural killer cell cytotoxicity against neuroblastoma cells. J Immunother. 2013 Jun; 36(5):319-29. PMID: 23719242.
      View in: PubMed
    36. Ara T, Nakata R, Sheard MA, Shimada H, Buettner R, Groshen SG, Ji L, Yu H, Jove R, Seeger RC, DeClerck YA. Critical role of STAT3 in IL-6-mediated drug resistance in human neuroblastoma. Cancer Res. 2013 Jul 01; 73(13):3852-64. PMID: 23633489.
      View in: PubMed
    37. Liu Y, Wu HW, Sheard MA, Sposto R, Somanchi SS, Cooper LJ, Lee DA, Seeger RC. Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy. Clin Cancer Res. 2013 Apr 15; 19(8):2132-43. PMID: 23378384.
      View in: PubMed
    38. Pugh TJ, Morozova O, Attiyeh EF, Asgharzadeh S, Wei JS, Auclair D, Carter SL, Cibulskis K, Hanna M, Kiezun A, Kim J, Lawrence MS, Lichenstein L, McKenna A, Pedamallu CS, Ramos AH, Shefler E, Sivachenko A, Sougnez C, Stewart C, Ally A, Birol I, Chiu R, Corbett RD, Hirst M, Jackman SD, Kamoh B, Khodabakshi AH, Krzywinski M, Lo A, Moore RA, Mungall KL, Qian J, Tam A, Thiessen N, Zhao Y, Cole KA, Diamond M, Diskin SJ, Mosse YP, Wood AC, Ji L, Sposto R, Badgett T, London WB, Moyer Y, Gastier-Foster JM, Smith MA, Guidry Auvil JM, Gerhard DS, Hogarty MD, Jones SJ, Lander ES, Gabriel SB, Getz G, Seeger RC, Khan J, Marra MA, Meyerson M, Maris JM. The genetic landscape of high-risk neuroblastoma. Nat Genet. 2013 Mar; 45(3):279-84. PMID: 23334666.
      View in: PubMed
    39. Asgharzadeh S, Salo JA, Ji L, Oberthuer A, Fischer M, Berthold F, Hadjidaniel M, Liu CW, Metelitsa LS, Pique-Regi R, Wakamatsu P, Villablanca JG, Kreissman SG, Matthay KK, Shimada H, London WB, Sposto R, Seeger RC. Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. J Clin Oncol. 2012 Oct 01; 30(28):3525-32. PMID: 22927533; PMCID: PMC3675667.
    40. Suganuma R, Wang LL, Sano H, Naranjo A, London WB, Seeger RC, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Amann G, Beiske K, Cullinane CJ, d'Amore ES, Gambini C, Jarzembowski JA, Joshi VV, Navarro S, Peuchmaur M, Shimada H. Peripheral neuroblastic tumors with genotype-phenotype discordance: a report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee. Pediatr Blood Cancer. 2013 Mar; 60(3):363-70. PMID: 22744966.
      View in: PubMed
    41. Yang F, Jove V, Buettner R, Xin H, Wu J, Wang Y, Nam S, Xu Y, Ara T, DeClerck YA, Seeger R, Yu H, Jove R. Sorafenib inhibits endogenous and IL-6/S1P induced JAK2-STAT3 signaling in human neuroblastoma, associated with growth suppression and apoptosis. Cancer Biol Ther. 2012 May; 13(7):534-41. PMID: 22406995.
      View in: PubMed
    42. Bosse KR, Diskin SJ, Cole KA, Wood AC, Schnepp RW, Norris G, Nguyen le B, Jagannathan J, Laquaglia M, Winter C, Diamond M, Hou C, Attiyeh EF, Mosse YP, Pineros V, Dizin E, Zhang Y, Asgharzadeh S, Seeger RC, Capasso M, Pawel BR, Devoto M, Hakonarson H, Rappaport EF, Irminger-Finger I, Maris JM. Common variation at BARD1 results in the expression of an oncogenic isoform that influences neuroblastoma susceptibility and oncogenicity. Cancer Res. 2012 Apr 15; 72(8):2068-78. PMID: 22350409.
      View in: PubMed
    43. Carpenter EL, Haglund EA, Mace EM, Deng D, Martinez D, Wood AC, Chow AK, Weiser DA, Belcastro LT, Winter C, Bresler SC, Vigny M, Mazot P, Asgharzadeh S, Seeger RC, Zhao H, Guo R, Christensen JG, Orange JS, Pawel BR, Lemmon MA, Mossé YP. Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma. Oncogene. 2012 Nov 15; 31(46):4859-67. PMID: 22266870.
      View in: PubMed
    44. Seeger RC. Immunology and immunotherapy of neuroblastoma. Semin Cancer Biol. 2011 Oct; 21(4):229-37. PMID: 21971567.
      View in: PubMed
    45. Delgado DC, Hank JA, Kolesar J, Lorentzen D, Gan J, Seo S, Kim K, Shusterman S, Gillies SD, Reisfeld RA, Yang R, Gadbaw B, DeSantes KB, London WB, Seeger RC, Maris JM, Sondel PM. Genotypes of NK cell KIR receptors, their ligands, and Fc? receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res. 2010 Dec 01; 70(23):9554-61. PMID: 20935224.
      View in: PubMed
    46. Shusterman S, London WB, Gillies SD, Hank JA, Voss SD, Seeger RC, Reynolds CP, Kimball J, Albertini MR, Wagner B, Gan J, Eickhoff J, DeSantes KB, Cohn SL, Hecht T, Gadbaw B, Reisfeld RA, Maris JM, Sondel PM. Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. J Clin Oncol. 2010 Nov 20; 28(33):4969-75. PMID: 20921469.
      View in: PubMed
    47. Baker DL, Schmidt ML, Cohn SL, Maris JM, London WB, Buxton A, Stram D, Castleberry RP, Shimada H, Sandler A, Shamberger RC, Look AT, Reynolds CP, Seeger RC, Matthay KK. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med. 2010 Sep 30; 363(14):1313-23. PMID: 20879880; PMCID: PMC2993160.
    48. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010 Sep 30; 363(14):1324-34. PMID: 20879881.
      View in: PubMed
    49. London WB, Frantz CN, Campbell LA, Seeger RC, Brumback BA, Cohn SL, Matthay KK, Castleberry RP, Diller L. Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study. J Clin Oncol. 2010 Aug 20; 28(24):3808-15. PMID: 20660830; PMCID: PMC2940398.
    50. Hölzel M, Huang S, Koster J, Ora I, Lakeman A, Caron H, Nijkamp W, Xie J, Callens T, Asgharzadeh S, Seeger RC, Messiaen L, Versteeg R, Bernards R. NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell. 2010 Jul 23; 142(2):218-29. PMID: 20655465.
      View in: PubMed
    51. Oberthuer A, Hero B, Berthold F, Juraeva D, Faldum A, Kahlert Y, Asgharzadeh S, Seeger R, Scaruffi P, Tonini GP, Janoueix-Lerosey I, Delattre O, Schleiermacher G, Vandesompele J, Vermeulen J, Speleman F, Noguera R, Piqueras M, Bénard J, Valent A, Avigad S, Yaniv I, Weber A, Christiansen H, Grundy RG, Schardt K, Schwab M, Eils R, Warnat P, Kaderali L, Simon T, Decarolis B, Theissen J, Westermann F, Brors B, Fischer M. Prognostic impact of gene expression-based classification for neuroblastoma. J Clin Oncol. 2010 Jul 20; 28(21):3506-15. PMID: 20567016.
      View in: PubMed
    52. Xiong G, Husseiny MI, Song L, Erdreich-Epstein A, Shackleford GM, Seeger RC, Jäckel D, Hensel M, Metelitsa LS. Novel cancer vaccine based on genes of Salmonella pathogenicity island 2. Int J Cancer. 2010 Jun 01; 126(11):2622-34. PMID: 19824039.
      View in: PubMed
    53. Bensimhon P, Villablanca JG, Sender LS, Matthay KK, Park JR, Seeger R, London WB, Yap JS, Kreissman SG. Peripheral blood stem cell support for multiple cycles of dose intensive induction therapy is feasible with little risk of tumor contamination in advanced stage neuroblastoma: a report from the Childrens Oncology Group. Pediatr Blood Cancer. 2010 Apr; 54(4):596-602. PMID: 20049927; PMCID: PMC2905158.
    54. Hu H, Du L, Nagabayashi G, Seeger RC, Gatti RA. ATM is down-regulated by N-Myc-regulated microRNA-421. Proc Natl Acad Sci U S A. 2010 Jan 26; 107(4):1506-11. PMID: 20080624; PMCID: PMC2824372.
    55. Okamatsu C, London WB, Naranjo A, Hogarty MD, Gastier-Foster JM, Look AT, LaQuaglia M, Maris JM, Cohn SL, Matthay KK, Seeger RC, Saji T, Shimada H. Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG. Pediatr Blood Cancer. 2009 Oct; 53(4):563-9. PMID: 19530234; PMCID: PMC2730988.
    56. Song L, Asgharzadeh S, Salo J, Engell K, Wu HW, Sposto R, Ara T, Silverman AM, DeClerck YA, Seeger RC, Metelitsa LS. Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. J Clin Invest. 2009 Jun; 119(6):1524-36. PMID: 19411762; PMCID: PMC2689106.
    57. Capasso M, Devoto M, Hou C, Asgharzadeh S, Glessner JT, Attiyeh EF, Mosse YP, Kim C, Diskin SJ, Cole KA, Bosse K, Diamond M, Laudenslager M, Winter C, Bradfield JP, Scott RH, Jagannathan J, Garris M, McConville C, London WB, Seeger RC, Grant SF, Li H, Rahman N, Rappaport E, Hakonarson H, Maris JM. Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nat Genet. 2009 Jun; 41(6):718-23. PMID: 19412175.
      View in: PubMed
    58. Beiske K, Burchill SA, Cheung IY, Hiyama E, Seeger RC, Cohn SL, Pearson AD, Matthay KK. Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force. Br J Cancer. 2009 May 19; 100(10):1627-37. PMID: 19401690.
      View in: PubMed
    59. Huang S, Laoukili J, Epping MT, Koster J, Hölzel M, Westerman BA, Nijkamp W, Hata A, Asgharzadeh S, Seeger RC, Versteeg R, Beijersbergen RL, Bernards R. ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome. Cancer Cell. 2009 Apr 07; 15(4):328-40. PMID: 19345331; PMCID: PMC2693316.
    60. Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, Gerbing RB, London WB, Villablanca JG. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol. 2009 Mar 01; 27(7):1007-13. PMID: 19171716; PMCID: PMC2738615.
    61. Park JR, Villablanca JG, London WB, Gerbing RB, Haas-Kogan D, Adkins ES, Attiyeh EF, Maris JM, Seeger RC, Reynolds CP, Matthay KK. Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2009 Jan; 52(1):44-50. PMID: 18937318; PMCID: PMC2731719.
    62. Ara T, Song L, Shimada H, Keshelava N, Russell HV, Metelitsa LS, Groshen SG, Seeger RC, DeClerck YA. Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells. Cancer Res. 2009 Jan 01; 69(1):329-37. PMID: 19118018.
      View in: PubMed
    63. Gilman AL, Ozkaynak MF, Matthay KK, Krailo M, Yu AL, Gan J, Sternberg A, Hank JA, Seeger R, Reaman GH, Sondel PM. Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group. J Clin Oncol. 2009 Jan 01; 27(1):85-91. PMID: 19047298; PMCID: PMC2645092.
    64. Chen QR, Song YK, Wei JS, Bilke S, Asgharzadeh S, Seeger RC, Khan J. An integrated cross-platform prognosis study on neuroblastoma patients. Genomics. 2008 Oct; 92(4):195-203. PMID: 18598751.
      View in: PubMed
    65. Neale G, Su X, Morton CL, Phelps D, Gorlick R, Lock RB, Reynolds CP, Maris JM, Friedman HS, Dome J, Khoury J, Triche TJ, Seeger RC, Gilbertson R, Khan J, Smith MA, Houghton PJ. Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res. 2008 Jul 15; 14(14):4572-83. PMID: 18628472.
      View in: PubMed
    66. Maris JM, Mosse YP, Bradfield JP, Hou C, Monni S, Scott RH, Asgharzadeh S, Attiyeh EF, Diskin SJ, Laudenslager M, Winter C, Cole KA, Glessner JT, Kim C, Frackelton EC, Casalunovo T, Eckert AW, Capasso M, Rappaport EF, McConville C, London WB, Seeger RC, Rahman N, Devoto M, Grant SF, Li H, Hakonarson H. Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. N Engl J Med. 2008 Jun 12; 358(24):2585-93. PMID: 18463370.
      View in: PubMed
    67. Feng L, Barnhart JR, Seeger RC, Wu L, Keshelava N, Huang SH, Jong A. Cdc6 knockdown inhibits human neuroblastoma cell proliferation. Mol Cell Biochem. 2008 Apr; 311(1-2):189-97. PMID: 18259842.
      View in: PubMed
    68. Pique-Regi R, Monso-Varona J, Ortega A, Seeger RC, Triche TJ, Asgharzadeh S. Sparse representation and Bayesian detection of genome copy number alterations from microarray data. Bioinformatics. 2008 Feb 01; 24(3):309-18. PMID: 18203770.
      View in: PubMed
    69. Ikegaki N, Gotoh T, Kung B, Riceberg JS, Kim DY, Zhao H, Rappaport EF, Hicks SL, Seeger RC, Tang XX. De novo identification of MIZ-1 (ZBTB17) encoding a MYC-interacting zinc-finger protein as a new favorable neuroblastoma gene. Clin Cancer Res. 2007 Oct 15; 13(20):6001-9. PMID: 17947461.
      View in: PubMed
    70. Song L, Ara T, Wu HW, Woo CW, Reynolds CP, Seeger RC, DeClerck YA, Thiele CJ, Sposto R, Metelitsa LS. Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma. J Clin Invest. 2007 Sep; 117(9):2702-12. PMID: 17710228.
      View in: PubMed
    71. Asgharzadeh S, Pique-Regi R, Sposto R, Wang H, Yang Y, Shimada H, Matthay K, Buckley J, Ortega A, Seeger RC. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J Natl Cancer Inst. 2006 Sep 06; 98(17):1193-203. PMID: 16954472.
      View in: PubMed
    72. Osenga KL, Hank JA, Albertini MR, Gan J, Sternberg AG, Eickhoff J, Seeger RC, Matthay KK, Reynolds CP, Twist C, Krailo M, Adamson PC, Reisfeld RA, Gillies SD, Sondel PM. A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group. Clin Cancer Res. 2006 Mar 15; 12(6):1750-9. PMID: 16551859; PMCID: PMC2587020.
    73. Tang XX, Zhao H, Kung B, Kim DY, Hicks SL, Cohn SL, Cheung NK, Seeger RC, Evans AE, Ikegaki N. The MYCN enigma: significance of MYCN expression in neuroblastoma. Cancer Res. 2006 Mar 01; 66(5):2826-33. PMID: 16510605.
      View in: PubMed
    74. Matthay KK, Tan JC, Villablanca JG, Yanik GA, Veatch J, Franc B, Twomey E, Horn B, Reynolds CP, Groshen S, Seeger RC, Maris JM. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study. J Clin Oncol. 2006 Jan 20; 24(3):500-6. PMID: 16421427.
      View in: PubMed
    75. Attiyeh EF, London WB, Mossé YP, Wang Q, Winter C, Khazi D, McGrady PW, Seeger RC, Look AT, Shimada H, Brodeur GM, Cohn SL, Matthay KK, Maris JM. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med. 2005 Nov 24; 353(21):2243-53. PMID: 16306521.
      View in: PubMed
    76. Schmidt ML, Lal A, Seeger RC, Maris JM, Shimada H, O'Leary M, Gerbing RB, Matthay KK. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study. J Clin Oncol. 2005 Sep 20; 23(27):6474-80. PMID: 16116154.
      View in: PubMed
    77. London WB, Castleberry RP, Matthay KK, Look AT, Seeger RC, Shimada H, Thorner P, Brodeur G, Maris JM, Reynolds CP, Cohn SL. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol. 2005 Sep 20; 23(27):6459-65. PMID: 16116153.
      View in: PubMed
    78. Kobayashi C, Monforte-Munoz HL, Gerbing RB, Stram DO, Matthay KK, Lukens JN, Seeger RC, Shimada H. Enlarged and prominent nucleoli may be indicative of MYCN amplification: a study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subtype with high mitosis-karyorrhexis index. Cancer. 2005 Jan 01; 103(1):174-80. PMID: 15549714.
      View in: PubMed
    79. Shimada H, Nakagawa A, Peters J, Wang H, Wakamatsu PK, Lukens JN, Matthay KK, Siegel SE, Seeger RC. TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance. Cancer. 2004 Oct 15; 101(8):1873-81. PMID: 15386308.
      View in: PubMed
    80. Roberts SS, Mori M, Pattee P, Lapidus J, Mathews R, O'Malley JP, Hsieh YC, Turner MA, Wang Z, Tian Q, Rodland MJ, Reynolds CP, Seeger RC, Nagalla SR. GABAergic system gene expression predicts clinical outcome in patients with neuroblastoma. J Clin Oncol. 2004 Oct 15; 22(20):4127-34. PMID: 15483022.
      View in: PubMed
    81. Metelitsa LS, Wu HW, Wang H, Yang Y, Warsi Z, Asgharzadeh S, Groshen S, Wilson SB, Seeger RC. Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2. J Exp Med. 2004 May 03; 199(9):1213-21. PMID: 15123743; PMCID: PMC2211904.
    82. Raetz EA, Kim MK, Moos P, Carlson M, Bruggers C, Hooper DK, Foot L, Liu T, Seeger R, Carroll WL. Identification of genes that are regulated transcriptionally by Myc in childhood tumors. Cancer. 2003 Aug 15; 98(4):841-53. PMID: 12910530.
      View in: PubMed
    83. Metelitsa LS, Weinberg KI, Emanuel PD, Seeger RC. Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells. Leukemia. 2003 Jun; 17(6):1068-77. PMID: 12764370.
      View in: PubMed
    84. Haas-Kogan DA, Swift PS, Selch M, Haase GM, Seeger RC, Gerbing RB, Stram DO, Matthay KK. Impact of radiotherapy for high-risk neuroblastoma: a Children's Cancer Group study. Int J Radiat Oncol Biol Phys. 2003 May 01; 56(1):28-39. PMID: 12694821.
      View in: PubMed
    85. Metelitsa LS, Gillies SD, Super M, Shimada H, Reynolds CP, Seeger RC. Antidisialoganglioside/granulocyte macrophage-colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on FcgammaRII (CD32) and Mac-1 (CD11b/CD18) for enhanced effector cell adhesion and azurophil granule exocytosis. Blood. 2002 Jun 01; 99(11):4166-73. PMID: 12010822.
      View in: PubMed
    86. Goto S, Umehara S, Gerbing RB, Stram DO, Brodeur GM, Seeger RC, Lukens JN, Matthay KK, Shimada H. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer. 2001 Nov 15; 92(10):2699-708. PMID: 11745206.
      View in: PubMed
    87. Anderson CP, Seeger RC, Satake N, Monforte-Munoz HL, Keshelava N, Bailey HH, Reynolds CP. Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line. J Pediatr Hematol Oncol. 2001 Nov; 23(8):500-5. PMID: 11878777.
      View in: PubMed
    88. Metelitsa LS, Naidenko OV, Kant A, Wu HW, Loza MJ, Perussia B, Kronenberg M, Seeger RC. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. J Immunol. 2001 Sep 15; 167(6):3114-22. PMID: 11544296.
      View in: PubMed
    89. Hoon DS, Kuo CT, Wen S, Wang H, Metelitsa L, Reynolds CP, Seeger RC. Ganglioside GM2/GD2 synthetase mRNA is a marker for detection of infrequent neuroblastoma cells in bone marrow. Am J Pathol. 2001 Aug; 159(2):493-500. PMID: 11485908.
      View in: PubMed
    90. Cooper R, Khakoo Y, Matthay KK, Lukens JN, Seeger RC, Stram DO, Gerbing RB, Nakagawa A, Shimada H. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: histopathologic features-a report from the Children's Cancer Group. Med Pediatr Oncol. 2001 Jun; 36(6):623-9. PMID: 11344493.
      View in: PubMed
    91. Rudnick E, Khakoo Y, Antunes NL, Seeger RC, Brodeur GM, Shimada H, Gerbing RB, Stram DO, Matthay KK. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the Children's Cancer Group Study. Med Pediatr Oncol. 2001 Jun; 36(6):612-22. PMID: 11344492.
      View in: PubMed
    92. Reynolds CP, Seeger RC. Detection of minimal residual disease in bone marrow during or after therapy as a prognostic marker for high-risk neuroblastoma. J Pediatr Hematol Oncol. 2001 Mar-Apr; 23(3):150-2. PMID: 11305717.
      View in: PubMed
    93. Thompson PM, Maris JM, Hogarty MD, Seeger RC, Reynolds CP, Brodeur GM, White PS. Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36 or at other tumor suppressor loci in neuroblastoma. Cancer Res. 2001 Jan 15; 61(2):679-86. PMID: 11212268.
      View in: PubMed
    94. Maris JM, Guo C, Blake D, White PS, Hogarty MD, Thompson PM, Rajalingam V, Gerbing R, Stram DO, Matthay KK, Seeger RC, Brodeur GM. Comprehensive analysis of chromosome 1p deletions in neuroblastoma. Med Pediatr Oncol. 2001 Jan; 36(1):32-6. PMID: 11464900.
      View in: PubMed
    95. Daniels JL, Olshan AF, Teschke K, Hertz-Picciotto I, Savitz DA, Blatt J, Bondy ML, Neglia JP, Pollock BH, Cohn SL, Look AT, Seeger RC, Castleberry RP. Residential pesticide exposure and neuroblastoma. Epidemiology. 2001 Jan; 12(1):20-7. PMID: 11138814.
      View in: PubMed
    96. Thompson PM, Seifried BA, Kyemba SK, Jensen SJ, Guo C, Maris JM, Brodeur GM, Stram DO, Seeger RC, Gerbing R, Matthay KK, Matise TC, White PS. Loss of heterozygosity for chromosome 14q in neuroblastoma. Med Pediatr Oncol. 2001 Jan; 36(1):28-31. PMID: 11464899.
      View in: PubMed
    97. Maris JM, Guo C, White PS, Hogarty MD, Thompson PM, Stram DO, Gerbing R, Matthay KK, Seeger RC, Brodeur GM. Allelic deletion at chromosome bands 11q14-23 is common in neuroblastoma. Med Pediatr Oncol. 2001 Jan; 36(1):24-7. PMID: 11464895.
      View in: PubMed
    98. Ozkaynak MF, Sondel PM, Krailo MD, Gan J, Javorsky B, Reisfeld RA, Matthay KK, Reaman GH, Seeger RC. Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study. J Clin Oncol. 2000 Dec 15; 18(24):4077-85. PMID: 11118469.
      View in: PubMed
    99. Seeger RC, Reynolds CP, Gallego R, Stram DO, Gerbing RB, Matthay KK. Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children's Cancer Group Study. J Clin Oncol. 2000 Dec 15; 18(24):4067-76. PMID: 11118468.
      View in: PubMed
    100. Choi LM, Kim NW, Zuo JJ, Gerbing R, Stram D, Lukens JN, Matthay KK, Seeger RC, Reynolds CP. Telomerase activity by TRAP assay and telomerase RNA (hTR) expression are predictive of outcome in neuroblastoma. Med Pediatr Oncol. 2000 Dec; 35(6):647-50. PMID: 11107138.
      View in: PubMed
    101. Goto H, Keshelava N, Matthay KK, Lukens JN, Gerbing RB, Stram DO, Seeger RC, Reynolds CP. Multidrug resistance-associated protein 1 (MRP1) expression in neuroblastoma cell lines and primary tumors. Med Pediatr Oncol. 2000 Dec; 35(6):619-22. PMID: 11107131.
      View in: PubMed
    102. Umehara S, Nakagawa A, Matthay KK, Lukens JN, Seeger RC, Stram DO, Gerbing RB, Shimada H. Histopathology defines prognostic subsets of ganglioneuroblastoma, nodular. Cancer. 2000 Sep 01; 89(5):1150-61. PMID: 10964346.
      View in: PubMed
    103. Yang Q, Olshan AF, Bondy ML, Shah NR, Pollock BH, Seeger RC, Look AT, Cohn SL. Parental smoking and alcohol consumption and risk of neuroblastoma. Cancer Epidemiol Biomarkers Prev. 2000 Sep; 9(9):967-72. PMID: 11008916.
      View in: PubMed
    104. Antunes NL, Khakoo Y, Matthay KK, Seeger RC, Stram DO, Gerstner E, Abrey LE, Dalmau J. Antineuronal antibodies in patients with neuroblastoma and paraneoplastic opsoclonus-myoclonus. J Pediatr Hematol Oncol. 2000 Jul-Aug; 22(4):315-20. PMID: 10959901.
      View in: PubMed
    105. Maris JM, Weiss MJ, Guo C, Gerbing RB, Stram DO, White PS, Hogarty MD, Sulman EP, Thompson PM, Lukens JN, Matthay KK, Seeger RC, Brodeur GM. Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study. J Clin Oncol. 2000 May; 18(9):1888-99. PMID: 10784629.
      View in: PubMed
    106. Schmidt ML, Lukens JN, Seeger RC, Brodeur GM, Shimada H, Gerbing RB, Stram DO, Perez C, Haase GM, Matthay KK. Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study. J Clin Oncol. 2000 Mar; 18(6):1260-8. PMID: 10715296.
      View in: PubMed
    107. Chen RL, Reynolds CP, Seeger RC. Neutrophils are cytotoxic and growth-inhibiting for neuroblastoma cells with an anti-GD2 antibody but, without cytotoxicity, can be growth-stimulating. Cancer Immunol Immunother. 2000 Feb; 48(11):603-12. PMID: 10663607.
      View in: PubMed
    108. Nickerson HJ, Matthay KK, Seeger RC, Brodeur GM, Shimada H, Perez C, Atkinson JB, Selch M, Gerbing RB, Stram DO, Lukens J. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study. J Clin Oncol. 2000 Feb; 18(3):477-86. PMID: 10653863.
      View in: PubMed
    109. Wang Y, Einhorn P, Triche TJ, Seeger RC, Reynolds CP. Expression of protein gene product 9.5 and tyrosine hydroxylase in childhood small round cell tumors. Clin Cancer Res. 2000 Feb; 6(2):551-8. PMID: 10690538.
      View in: PubMed
    110. Erdreich-Epstein A, Shimada H, Groshen S, Liu M, Metelitsa LS, Kim KS, Stins MF, Seeger RC, Durden DL. Integrins alpha(v)beta3 and alpha(v)beta5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide. Cancer Res. 2000 Feb 01; 60(3):712-21. PMID: 10676658.
      View in: PubMed
    111. Perez CA, Matthay KK, Atkinson JB, Seeger RC, Shimada H, Haase GM, Stram DO, Gerbing RB, Lukens JN. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study. J Clin Oncol. 2000 Jan; 18(1):18-26. PMID: 10623689.
      View in: PubMed
    112. Olshan AF, Smith J, Cook MN, Grufferman S, Pollock BH, Stram DO, Seeger RC, Look AT, Cohn SL, Castleberry RP, Bondy ML. Hormone and fertility drug use and the risk of neuroblastoma: a report from the Children's Cancer Group and the Pediatric Oncology Group. Am J Epidemiol. 1999 Nov 01; 150(9):930-8. PMID: 10547138.
      View in: PubMed
    113. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB, Reynolds CP. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med. 1999 Oct 14; 341(16):1165-73. PMID: 10519894.
      View in: PubMed
    114. Guo C, White PS, Weiss MJ, Hogarty MD, Thompson PM, Stram DO, Gerbing R, Matthay KK, Seeger RC, Brodeur GM, Maris JM. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene. 1999 Sep 02; 18(35):4948-57. PMID: 10490829.
      View in: PubMed
    115. Maurer BJ, Metelitsa LS, Seeger RC, Cabot MC, Reynolds CP. Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)- retinamide in neuroblastoma cell lines. J Natl Cancer Inst. 1999 Jul 07; 91(13):1138-46. PMID: 10393722.
      View in: PubMed
    116. DuBois SG, Kalika Y, Lukens JN, Brodeur GM, Seeger RC, Atkinson JB, Haase GM, Black CT, Perez C, Shimada H, Gerbing R, Stram DO, Matthay KK. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol. 1999 May-Jun; 21(3):181-9. PMID: 10363850.
      View in: PubMed
    117. Sugiura Y, Ma L, Sun B, Shimada H, Laug WE, Seeger RC, DeClerck YA. The plasminogen-plasminogen activator (PA) system in neuroblastoma: role of PA inhibitor-1 in metastasis. Cancer Res. 1999 Mar 15; 59(6):1327-36. PMID: 10096567.
      View in: PubMed
    118. Keshelava N, Seeger RC, Groshen S, Reynolds CP. Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res. 1998 Dec 01; 58(23):5396-405. PMID: 9850071.
      View in: PubMed
    119. Goldberg SS, DeSantes K, Huberty JP, Price D, Hasegawa BH, Reynolds CP, Seeger RC, Hattner R, Matthay KK. Engraftment after myeloablative doses of 131I-metaiodobenzylguanidine followed by autologous bone marrow transplantation for treatment of refractory neuroblastoma. Med Pediatr Oncol. 1998 Jun; 30(6):339-46. PMID: 9589082.
      View in: PubMed
    120. Sugiura Y, Shimada H, Seeger RC, Laug WE, DeClerck YA. Matrix metalloproteinases-2 and -9 are expressed in human neuroblastoma: contribution of stromal cells to their production and correlation with metastasis. Cancer Res. 1998 May 15; 58(10):2209-16. PMID: 9605768.
      View in: PubMed
    121. Matthay KK, Perez C, Seeger RC, Brodeur GM, Shimada H, Atkinson JB, Black CT, Gerbing R, Haase GM, Stram DO, Swift P, Lukens JN. Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study. J Clin Oncol. 1998 Apr; 16(4):1256-64. PMID: 9552023.
      View in: PubMed
    122. Ozkaynak MF, Matthay K, Cairo M, Harris RE, Feig S, Reynolds CP, Buckley J, Villablanca JG, Seeger RC. Double-alkylator non-total-body irradiation regimen with autologous hematopoietic stem-cell transplantation in pediatric solid tumors. J Clin Oncol. 1998 Mar; 16(3):937-44. PMID: 9508176.
      View in: PubMed
    123. Seeger RC, Rosenblatt JD, Duerst RE, Reynolds CP, Villablanca JG, Hasenauer B, Feig SA. A Phase I study of human gamma interferon gene-transduced tumor cells in patients with neuroblastoma. Hum Gene Ther. 1998 Feb 10; 9(3):379-90. PMID: 9508055.
      View in: PubMed
    124. Matthay KK, DeSantes K, Hasegawa B, Huberty J, Hattner RS, Ablin A, Reynolds CP, Seeger RC, Weinberg VK, Price D. Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol. 1998 Jan; 16(1):229-36. PMID: 9440747.
      View in: PubMed
    125. Castleberry RP, Pritchard J, Ambros P, Berthold F, Brodeur GM, Castel V, Cohn SL, De Bernardi B, Dicks-Mireaux C, Frappaz D, Haase GM, Haber M, Jones DR, Joshi VV, Kaneko M, Kemshead JT, Kogner P, Lee RE, Matthay KK, Michon JM, Monclair R, Roald BR, Seeger RC, Shaw PJ, Shuster JJ. The International Neuroblastoma Risk Groups (INRG): a preliminary report. Eur J Cancer. 1997 Oct; 33(12):2113-6. PMID: 9516864.
      View in: PubMed
    126. Keshelava N, Seeger RC, Reynolds CP. Drug resistance in human neuroblastoma cell lines correlates with clinical therapy. Eur J Cancer. 1997 Oct; 33(12):2002-6. PMID: 9516842.
      View in: PubMed
    127. Reynolds CP, Zuo JJ, Kim NW, Wang H, Lukens JN, Matthay KK, Seeger RC. Telomerase expression in primary neuroblastomas. Eur J Cancer. 1997 Oct; 33(12):1929-31. PMID: 9516826.
      View in: PubMed
    128. Frost JD, Hank JA, Reaman GH, Frierdich S, Seeger RC, Gan J, Anderson PM, Ettinger LJ, Cairo MS, Blazar BR, Krailo MD, Matthay KK, Reisfeld RA, Sondel PM. A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group. Cancer. 1997 Jul 15; 80(2):317-33. PMID: 9217046.
      View in: PubMed
    129. Feng L, Miyake M, Seeger RC, Bogenmann E. Wild-type DNA sequence of the N-myc transactivation domain in human neuroblastoma. Int J Cancer. 1997 Jun 11; 71(6):1116-7. PMID: 9185720.
      View in: PubMed
    130. Franks LM, Bollen A, Seeger RC, Stram DO, Matthay KK. Neuroblastoma in adults and adolescents: an indolent course with poor survival. Cancer. 1997 May 15; 79(10):2028-35. PMID: 9149032.
      View in: PubMed
    131. Plantaz D, Mohapatra G, Matthay KK, Pellarin M, Seeger RC, Feuerstein BG. Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization. Am J Pathol. 1997 Jan; 150(1):81-9. PMID: 9006325.
      View in: PubMed
    132. Stram DO, Matthay KK, O'Leary M, Reynolds CP, Haase GM, Atkinson JB, Brodeur GM, Seeger RC. Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group studies. J Clin Oncol. 1996 Sep; 14(9):2417-26. PMID: 8823319.
      View in: PubMed
    133. Haase GM, O'Leary MC, Stram DO, Lukens JN, Seeger RC, Shimada H, Matthay KK. Pelvic neuroblastoma--implications for a new favorable subgroup: a Children's Cancer Group experience. Ann Surg Oncol. 1995 Nov; 2(6):516-23. PMID: 8591082.
      View in: PubMed
    134. Shimada H, Stram DO, Chatten J, Joshi VV, Hachitanda Y, Brodeur GM, Lukens JN, Matthay KK, Seeger RC. Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis. J Natl Cancer Inst. 1995 Oct 04; 87(19):1470-6. PMID: 7674334.
      View in: PubMed
    135. Uçar K, Seeger RC, Challita PM, Watanabe CT, Yen TL, Morgan JP, Amado R, Chou E, McCallister T, Barber JR. Sustained cytokine production and immunophenotypic changes in human neuroblastoma cell lines transduced with a human gamma interferon vector. Cancer Gene Ther. 1995 Sep; 2(3):171-81. PMID: 8528960.
      View in: PubMed
    136. Wada M, Seeger RC, Mizoguchi H, Koeffler HP. Maintenance of normal imprinting of H19 and IGF2 genes in neuroblastoma. Cancer Res. 1995 Aug 01; 55(15):3386-8. PMID: 7614476.
      View in: PubMed
    137. Villablanca JG, Khan AA, Avramis VI, Seeger RC, Matthay KK, Ramsay NK, Reynolds CP. Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation. J Clin Oncol. 1995 Apr; 13(4):894-901. PMID: 7707116.
      View in: PubMed
    138. Matthay KK, O'Leary MC, Ramsay NK, Villablanca J, Reynolds CP, Atkinson JB, Haase GM, Stram DO, Seeger RC. Role of myeloablative therapy in improved outcome for high risk neuroblastoma: review of recent Children's Cancer Group results. Eur J Cancer. 1995; 31A(4):572-5. PMID: 7576971.
      View in: PubMed
    139. Cohen PS, Chan JP, Lipkunskaya M, Biedler JL, Seeger RC. Expression of stem cell factor and c-kit in human neuroblastoma. The Children's Cancer Group. Blood. 1994 Nov 15; 84(10):3465-72. PMID: 7524740.
      View in: PubMed
    140. Matthay KK, Seeger RC, Reynolds CP, Stram DO, O'Leary MC, Harris RE, Selch M, Atkinson JB, Haase GM, Ramsay NK. Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: a report from the Childrens Cancer Group. J Clin Oncol. 1994 Nov; 12(11):2382-9. PMID: 7964954.
      View in: PubMed
    141. Ortiz SS, Miller JH, Villablanca JG, Seeger RC. Bone abnormalities detected with skeletal scintigraphy after bone marrow harvest in patients with childhood neuroblastoma. Radiology. 1994 Sep; 192(3):755-8. PMID: 8058943.
      View in: PubMed
    142. Ungar DR, Hailat N, Strahler JR, Kuick RD, Brodeur GM, Seeger RC, Reynolds CP, Hanash SM. Hsp27 expression in neuroblastoma: correlation with disease stage. J Natl Cancer Inst. 1994 May 18; 86(10):780-4. PMID: 8169976.
      View in: PubMed
    143. Huang SH, Tang A, Drisco B, Zhang SQ, Seeger R, Li C, Jong A. Human dTMP kinase: gene expression and enzymatic activity coinciding with cell cycle progression and cell growth. DNA Cell Biol. 1994 May; 13(5):461-71. PMID: 8024690.
      View in: PubMed
    144. Stram DO, Matthay KK, O'Leary M, Reynolds CP, Seeger RC. Myeloablative chemoradiotherapy versus continued chemotherapy for high risk neuroblastoma. Prog Clin Biol Res. 1994; 385:287-91. PMID: 7972222.
      View in: PubMed
    145. Matthay KK, Seeger RC, Reynolds CP, Stram DO, O'Leary M, Harris RE, Selch M, Atkinson JB, Haase G, Hammond GD. Comparison of autologous and allogeneic bone marrow transplantation for neuroblastoma. Prog Clin Biol Res. 1994; 385:301-7. PMID: 7972225.
      View in: PubMed
    146. Hank JA, Surfus J, Gan J, Chew TL, Hong R, Tans K, Reisfeld R, Seeger RC, Reynolds CP, Bauer M. Treatment of neuroblastoma patients with antiganglioside GD2 antibody plus interleukin-2 induces antibody-dependent cellular cytotoxicity against neuroblastoma detected in vitro. J Immunother Emphasis Tumor Immunol. 1994 Jan; 15(1):29-37. PMID: 8110728.
      View in: PubMed
    147. Tanaka T, Seeger RC, Tanabe M, Hiyama E, Shimoda H, Ida N. Prognostic prediction in neuroblastomas: clinical significance of combined analysis for Ha-ras p21 expression and N-myc gene amplification. Cancer Detect Prev. 1994; 18(4):283-9. PMID: 7982238.
      View in: PubMed
    148. Miyake M, Suzuki T, Shimada H, Stram D, Seeger RC. High affinity nerve growth factor receptor expression (gp140trkA), N-myc amplification, histopathology, and survival in neuroblastoma. Prog Clin Biol Res. 1994; 385:163-8. PMID: 7972208.
      View in: PubMed
    149. Wada RK, Seeger RC, Brodeur GM, Einhorn PA, Rayner SA, Tomayko MM, Reynolds CP. Human neuroblastoma cell lines that express N-myc without gene amplification. Cancer. 1993 Dec 01; 72(11):3346-54. PMID: 8242562.
      View in: PubMed
    150. Matthay KK, Atkinson JB, Stram DO, Selch M, Reynolds CP, Seeger RC. Patterns of relapse after autologous purged bone marrow transplantation for neuroblastoma: a Childrens Cancer Group pilot study. J Clin Oncol. 1993 Nov; 11(11):2226-33. PMID: 8229138.
      View in: PubMed
    151. Srivatsan ES, Ying KL, Seeger RC. Deletion of chromosome 11 and of 14q sequences in neuroblastoma. Genes Chromosomes Cancer. 1993 May; 7(1):32-7. PMID: 7688553.
      View in: PubMed
    152. Leone A, Seeger RC, Hong CM, Hu YY, Arboleda MJ, Brodeur GM, Stram D, Slamon DJ, Steeg PS. Evidence for nm23 RNA overexpression, DNA amplification and mutation in aggressive childhood neuroblastomas. Oncogene. 1993 Apr; 8(4):855-65. PMID: 8384356.
      View in: PubMed
    153. Campbell LA, Seeger RC, Harris RE, Villablanca JG, Matthay KK. Escalating dose of continuous infusion combination chemotherapy for refractory neuroblastoma. J Clin Oncol. 1993 Apr; 11(4):623-9. PMID: 8478657.
      View in: PubMed
    154. Suzuki T, Bogenmann E, Shimada H, Stram D, Seeger RC. Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas. J Natl Cancer Inst. 1993 Mar 03; 85(5):377-84. PMID: 8433391.
      View in: PubMed
    155. Keim DR, Hailat N, Kuick R, Reynolds CP, Brodeur GM, Seeger RC, Hanash SM. PCNA levels in neuroblastoma are increased in tumors with an amplified N-myc gene and in metastatic stage tumors. Clin Exp Metastasis. 1993 Jan; 11(1):83-90. PMID: 8093685.
      View in: PubMed
    156. Crabbe DC, Peters J, Seeger RC. Rapid detection of MYCN gene amplification in neuroblastomas using the polymerase chain reaction. Diagn Mol Pathol. 1992 Dec; 1(4):229-34. PMID: 1342970.
      View in: PubMed
    157. Wada RK, Seeger RC, Reynolds CP, Alloggiamento T, Yamashiro JM, Ruland C, Black AC, Rosenblatt JD. Cell type-specific expression and negative regulation by retinoic acid of the human N-myc promoter in neuroblastoma cells. Oncogene. 1992 Apr; 7(4):711-7. PMID: 1565467.
      View in: PubMed
    158. Tanaka T, Slamon DJ, Shimada H, Shimoda H, Fujisawa T, Ida N, Seeger RC. A significant association of Ha-ras p21 in neuroblastoma cells with patient prognosis. A retrospective study of 103 cases. Cancer. 1991 Sep 15; 68(6):1296-302. PMID: 1873783.
      View in: PubMed
    159. Haase GM, O'Leary MC, Ramsay NK, Romansky SG, Stram DO, Seeger RC, Hammond GD. Aggressive surgery combined with intensive chemotherapy improves survival in poor-risk neuroblastoma. J Pediatr Surg. 1991 Sep; 26(9):1119-23; discussion 1123-4. PMID: 1941492.
      View in: PubMed
    160. Hailat N, Keim DR, Melhem RF, Zhu XX, Eckerskorn C, Brodeur GM, Reynolds CP, Seeger RC, Lottspeich F, Strahler JR. High levels of p19/nm23 protein in neuroblastoma are associated with advanced stage disease and with N-myc gene amplification. J Clin Invest. 1991 Jul; 88(1):341-5. PMID: 2056128.
      View in: PubMed
    161. Seeger RC, Reynolds CP. Treatment of high-risk solid tumors of childhood with intensive therapy and autologous bone marrow transplantation. Pediatr Clin North Am. 1991 Apr; 38(2):393-424. PMID: 2006084.
      View in: PubMed
    162. Moss TJ, Reynolds CP, Sather HN, Romansky SG, Hammond GD, Seeger RC. Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma. N Engl J Med. 1991 Jan 24; 324(4):219-26. PMID: 1985243.
      View in: PubMed
    163. Reynolds CP, Kane DJ, Einhorn PA, Matthay KK, Crouse VL, Wilbur JR, Shurin SB, Seeger RC. Response of neuroblastoma to retinoic acid in vitro and in vivo. Prog Clin Biol Res. 1991; 366:203-11. PMID: 2068138.
      View in: PubMed
    164. Seeger RC, Villablanca JG, Matthay KK, Harris R, Moss TJ, Feig SA, Selch M, Ramsay N, Reynolds CP. Intensive chemoradiotherapy and autologous bone marrow transplantation for poor prognosis neuroblastoma. Prog Clin Biol Res. 1991; 366:527-33. PMID: 2068169.
      View in: PubMed
    165. Srivatsan ES, Murali V, Seeger RC. Loss of heterozygosity for alleles on chromosomes 11q and 14q in neuroblastoma. Prog Clin Biol Res. 1991; 366:91-8. PMID: 2068183.
      View in: PubMed
    166. Hailat N, Strahler J, Melhem R, Zhu XX, Brodeur G, Seeger RC, Reynolds CP, Hanash S. N-myc gene amplification in neuroblastoma is associated with altered phosphorylation of a proliferation related polypeptide (Op18). Oncogene. 1990 Nov; 5(11):1615-8. PMID: 2267130.
      View in: PubMed
    167. Cohen PS, Cooper MJ, Helman LJ, Thiele CJ, Seeger RC, Israel MA. Neuropeptide Y expression in the developing adrenal gland and in childhood neuroblastoma tumors. Cancer Res. 1990 Sep 15; 50(18):6055-61. PMID: 2393870.
      View in: PubMed
    168. Hsiao RJ, Seeger RC, Yu AL, O'Connor DT. Chromogranin A in children with neuroblastoma. Serum concentration parallels disease stage and predicts survival. J Clin Invest. 1990 May; 85(5):1555-9. PMID: 2332506.
      View in: PubMed
    169. Smith EI, Haase GM, Seeger RC, Brodeur GM. A surgical perspective on the current staging in neuroblastoma--the International Neuroblastoma Staging System proposal. J Pediatr Surg. 1989 Apr; 24(4):386-90. PMID: 2732883.
      View in: PubMed
    170. Matthay KK, Sather HN, Seeger RC, Haase GM, Hammond GD. Excellent outcome of stage II neuroblastoma is independent of residual disease and radiation therapy. J Clin Oncol. 1989 Feb; 7(2):236-44. PMID: 2915240.
      View in: PubMed
    171. Brodeur GM, Seeger RC, Barrett A, Berthold F, Castleberry RP, D'Angio G, De Bernardi B, Evans AE, Favrot M, Freeman AI. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol. 1988 Dec; 6(12):1874-81. PMID: 3199170.
      View in: PubMed
    172. Moss TJ, Rosenblatt HM, Seeger RC. Expression of a developmental stage-specific antigen by neuronal precursor cells of human fetal cerebellum. J Neuroimmunol. 1988 Nov; 20(1):3-14. PMID: 3183035.
      View in: PubMed
    173. Cohen PS, Seeger RC, Triche TJ, Israel MA. Detection of N-myc gene expression in neuroblastoma tumors by in situ hybridization. Am J Pathol. 1988 Jun; 131(3):391-7. PMID: 2454580.
      View in: PubMed
    174. Zehnbauer BA, Small D, Brodeur GM, Seeger R, Vogelstein B. Characterization of N-myc amplification units in human neuroblastoma cells. Mol Cell Biol. 1988 Feb; 8(2):522-30. PMID: 2832725.
      View in: PubMed
    175. Moss TJ, Law YM, Slamon DJ, Brodeur GM, Seeger RC. N-myc protein expression by neuroblastoma cells that have metastasized to bone marrow. Prog Clin Biol Res. 1988; 271:91-101. PMID: 3406026.
      View in: PubMed
    176. Brodeur GM, Fong CT, Morita M, Griffith R, Hayes FA, Seeger RC. Molecular analysis and clinical significance of N-myc amplification and chromosome 1p monosomy in human neuroblastomas. Prog Clin Biol Res. 1988; 271:3-15. PMID: 3043452.
      View in: PubMed
    177. Brodeur GM, Seeger RC, Barrett A, Castleberry RP, D'Angio G, De Bernardi B, Evans AE, Favrot M, Freeman AI, Haase G. International criteria for diagnosis, staging and response to treatment in patients with neuroblastoma. Prog Clin Biol Res. 1988; 271:509-24. PMID: 3406015.
      View in: PubMed
    178. Seeger RC, Wada R, Brodeur GM, Moss TJ, Bjork RL, Sousa L, Slamon DJ. Expression of N-myc by neuroblastomas with one or multiple copies of the oncogene. Prog Clin Biol Res. 1988; 271:41-9. PMID: 3406010.
      View in: PubMed
    179. Reynolds CP, Tomayko MM, Donner L, Helson L, Seeger RC, Triche TJ, Brodeur GM. Biological classification of cell lines derived from human extra-cranial neural tumors. Prog Clin Biol Res. 1988; 271:291-306. PMID: 3406003.
      View in: PubMed
    180. Seeger RC, Moss TJ, Feig SA, Lenarsky C, Selch M, Ramsay N, Harris R, Wells J, Sather H, Reynolds CP. Bone marrow transplantation for poor prognosis neuroblastoma. Prog Clin Biol Res. 1988; 271:203-13. PMID: 3043448.
      View in: PubMed
    181. Wada RK, Seeger RC, Brodeur GM, Slamon DJ, Rayner SA, Tomayko M, Reynolds CP. Characterization of human neuroblastoma cell lines that lack N-myc gene amplification. Prog Clin Biol Res. 1988; 271:57-69. PMID: 3406020.
      View in: PubMed
    182. McGuire WL, Johnson BE, Seeger RC, Slamon DJ. Oncogenes in clinical cancer--a panel discussion. Breast Cancer Res Treat. 1987 Dec; 10(3):217-27. PMID: 2833962.
      View in: PubMed
    183. Moss TJ, Fonkalsrud EW, Feig SA, Lenarsky C, Selch M, Wells J, Seeger RC. Delayed surgery and bone marrow transplantation for widespread neuroblastoma. Ann Surg. 1987 Oct; 206(4):514-20. PMID: 3310932; PMCID: PMC1493234.
    184. Brodeur GM, Hayes FA, Green AA, Casper JT, Wasson J, Wallach S, Seeger RC. Consistent N-myc copy number in simultaneous or consecutive neuroblastoma samples from sixty individual patients. Cancer Res. 1987 Aug 15; 47(16):4248-53. PMID: 2440561.
      View in: PubMed
    185. Ladisch S, Wu ZL, Feig S, Ulsh L, Schwartz E, Floutsis G, Wiley F, Lenarsky C, Seeger R. Shedding of GD2 ganglioside by human neuroblastoma. Int J Cancer. 1987 Jan 15; 39(1):73-6. PMID: 3539825.
      View in: PubMed
    186. Butturini A, Bortin MM, Seeger RC, Gale RP. Graft-vs-leukemia following bone marrow transplantation: a model of immunotherapy in man. Prog Clin Biol Res. 1987; 244:371-90. PMID: 3310000.
      View in: PubMed
    187. Reynolds CP, Seeger RC, Vo DD, Black AT, Wells J, Ugelstad J. Model system for removing neuroblastoma cells from bone marrow using monoclonal antibodies and magnetic immunobeads. Cancer Res. 1986 Nov; 46(11):5882-6. PMID: 3756928.
      View in: PubMed
    188. Butturini A, Seeger RC, Gale RP. Recipient immune-competent T lymphocytes can survive intensive conditioning for bone marrow transplantation. Blood. 1986 Oct; 68(4):954-6. PMID: 2944556.
      View in: PubMed
    189. Shiloh Y, Korf B, Kohl NE, Sakai K, Brodeur GM, Harris P, Kanda N, Seeger RC, Alt F, Latt SA. Amplification and rearrangement of DNA sequences from the chromosomal region 2p24 in human neuroblastomas. Cancer Res. 1986 Oct; 46(10):5297-301. PMID: 3756879.
      View in: PubMed
    190. Brodeur GM, Seeger RC, Sather H, Dalton A, Siegel SE, Wong KY, Hammond D. Clinical implications of oncogene activation in human neuroblastomas. Cancer. 1986 Jul 15; 58(2 Suppl):541-5. PMID: 3719548.
      View in: PubMed
    191. Slamon DJ, Boone TC, Seeger RC, Keith DE, Chazin V, Lee HC, Souza LM. Identification and characterization of the protein encoded by the human N-myc oncogene. Science. 1986 May 09; 232(4751):768-72. PMID: 3008339.
      View in: PubMed
    192. Kinzler KW, Zehnbauer BA, Brodeur GM, Seeger RC, Trent JM, Meltzer PS, Vogelstein B. Amplification units containing human N-myc and c-myc genes. Proc Natl Acad Sci U S A. 1986 Feb; 83(4):1031-5. PMID: 3006024.
      View in: PubMed
    193. Brodeur GM, Seeger RC. Gene amplification in human neuroblastomas: basic mechanisms and clinical implications. Cancer Genet Cytogenet. 1986 Jan 01; 19(1-2):101-11. PMID: 3940169.
      View in: PubMed
    194. Wu ZL, Schwartz E, Seeger R, Ladisch S. Expression of GD2 ganglioside by untreated primary human neuroblastomas. Cancer Res. 1986 Jan; 46(1):440-3. PMID: 3940209.
      View in: PubMed
    195. Seeger RC, Vo DD, Ugelstad J, Reynolds CP. Removal of neuroblastoma cells from bone marrow with monoclonal antibodies and magnetic immunobeads. Prog Clin Biol Res. 1986; 211:285-93. PMID: 3515362.
      View in: PubMed
    196. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, Hammond D. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med. 1985 Oct 31; 313(18):1111-6. PMID: 4047115.
      View in: PubMed
    197. Hann HW, Evans AE, Siegel SE, Wong KY, Sather H, Dalton A, Hammond D, Seeger RC. Prognostic importance of serum ferritin in patients with Stages III and IV neuroblastoma: the Childrens Cancer Study Group experience. Cancer Res. 1985 Jun; 45(6):2843-8. PMID: 3986811.
      View in: PubMed
    198. Bernstein I, Kersey J, Seeger R, Andrews R. Immunodiagnosis and immunotherapy of childhood malignancies. Pediatr Clin North Am. 1985 Jun; 32(3):575-99. PMID: 3889799.
      View in: PubMed
    199. Shiloh Y, Shipley J, Brodeur GM, Bruns G, Korf B, Donlon T, Schreck RR, Seeger R, Sakai K, Latt SA. Differential amplification, assembly, and relocation of multiple DNA sequences in human neuroblastomas and neuroblastoma cell lines. Proc Natl Acad Sci U S A. 1985 Jun; 82(11):3761-5. PMID: 3858848.
      View in: PubMed
    200. Reynolds CP, Moss TJ, Seeger RC, Black AT, Woody JN. Sensitive detection of neuroblastoma cells in bone marrow for monitoring the efficacy of marrow purging procedures. Prog Clin Biol Res. 1985; 175:425-41. PMID: 2581273.
      View in: PubMed
    201. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc sequences in primary human neuroblastomas: correlation with advanced disease stage. Prog Clin Biol Res. 1985; 175:105-13. PMID: 3991726.
      View in: PubMed
    202. Sugimoto T, Sawada T, Negoro S, Kidowaki T, Morioka H, Matsumura T, Kemshead JT, Seeger RC. Altered expression of cell surface membrane antigens in a common acute lymphoblastic leukemia-associated antigen-expressing neuroblastoma cell line (SJ-N-CG) with morphological differentiation. Cancer Res. 1985 Jan; 45(1):358-64. PMID: 2981159.
      View in: PubMed
    203. Donner L, Triche TJ, Israel MA, Seeger RC, Reynolds CP. A panel of monoclonal antibodies which discriminate neuroblastoma from Ewing's sarcoma, rhabdomyosarcoma, neuroepithelioma, and hematopoietic malignancies. Prog Clin Biol Res. 1985; 175:347-66. PMID: 3991736.
      View in: PubMed
    204. Zeltzer PM, Marangos PJ, Sather H, Evans A, Siegel S, Wong KY, Dalton A, Seeger R, Hammond D. Prognostic importance of serum neuron specific enolase in local and widespread neuroblastoma. Prog Clin Biol Res. 1985; 175:319-29. PMID: 3991735.
      View in: PubMed
    205. D'Angio GJ, August C, Elkins W, Evans AE, Seeger R, Lenarsky C, Feig S, Wells J, Ramsay N, Kim T. Metastatic neuroblastoma managed by supralethal therapy and bone marrow reconstitution (BMRc). Results of a four-institution Children's Cancer Study Group pilot study. Prog Clin Biol Res. 1985; 175:557-63. PMID: 3887431.
      View in: PubMed
    206. Moss TJ, Seeger RC, Kindler-Rohrborn A, Marangos PJ, Rajewsky MF, Reynolds CP. Immunohistologic detection and phenotyping of neuroblastoma cells in bone marrow using cytoplasmic neuron specific enolase and cell surface antigens. Prog Clin Biol Res. 1985; 175:367-78. PMID: 3991737.
      View in: PubMed
    207. Seeger RC, Reynolds CP, Vo DD, Ugelstad J, Wells J. Depletion of neuroblastoma cells from bone marrow with monoclonal antibodies and magnetic immunobeads. Prog Clin Biol Res. 1985; 175:443-58. PMID: 3887429.
      View in: PubMed
    208. Hanash SM, Gagnon M, Seeger RC, Baier L. Analysis of neuroblastoma cell proteins using two-dimensional electrophoresis. Prog Clin Biol Res. 1985; 175:261-8. PMID: 3991732.
      View in: PubMed
    209. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984 Jun 08; 224(4653):1121-4. PMID: 6719137.
      View in: PubMed
    210. Sidell N, Altman A, Haussler MR, Seeger RC. Effects of retinoic acid (RA) on the growth and phenotypic expression of several human neuroblastoma cell lines. Exp Cell Res. 1983 Oct; 148(1):21-30. PMID: 6313408.
      View in: PubMed
    211. Zeltzer PM, Marangos PJ, Parma AM, Sather H, Dalton A, Hammond D, Siegel SE, Seeger RC. Raised neuron-specific enolase in serum of children with metastatic neuroblastoma. A report from the Children's Cancer Study Group. Lancet. 1983 Aug 13; 2(8346):361-3. PMID: 6135871.
      View in: PubMed
    212. Seeger RC, Siegel SE, Sidell N. Neuroblastoma: clinical perspectives, monoclonal antibodies, and retinoic acid. Ann Intern Med. 1982 Dec; 97(6):873-84. PMID: 6756240.
      View in: PubMed
    213. Seeger RC, Danon YL, Rayner SA, Hoover F. Definition of a Thy-1 determinant on human neuroblastoma, glioma, sarcoma, and teratoma cells with a monoclonal antibody. J Immunol. 1982 Feb; 128(2):983-9. PMID: 6172518.
      View in: PubMed
    214. Seeger RC, Rosenblatt HM, Imai K, Ferrone S. Common antigenic determinants on human melanoma, glioma, neuroblastoma, and sarcoma cells defined with monoclonal antibodies. Cancer Res. 1981 Jul; 41(7):2714-7. PMID: 6166367.
      View in: PubMed
    215. Howe AJ, Seeger RC, Molinaro GA, Ferrone S. Analysis of human tumor cells for Ia-like antigens with monoclonal antibodies. J Natl Cancer Inst. 1981 May; 66(5):827-9. PMID: 6262557.
      View in: PubMed
    216. Siegel MM, Chung HS, Rucker N, Siegel SE, Seeger RC, Isaacs H, Benedict WF. In vitro and in vivo preclinical chemotherapy studies of human neuroblastoma. Cancer Treat Rep. 1980 Aug-Sep; 64(8-9):975-9. PMID: 7448832.
      View in: PubMed
    217. Danon YL, Seeger RC, Maidman JE. Fetal neural antigens on human neuroblastoma cells. J Immunol. 1980 Jun; 124(6):2925-9. PMID: 6246171.
      View in: PubMed
    218. Arenson EB, Epstein MB, Seeger RC. Volumetric and functional heterogeneity of human monocytes. J Clin Invest. 1980 Mar; 65(3):613-8. PMID: 7354131.
      View in: PubMed
    219. Danon YL, Epstein MB, Siegel MM, Rucker N, Myers CP, Norman A, Benedict WF, Seeger RC. Variability in DNA distributions of human neuroblastomas after cyclophosphamide. Cancer Treat Rep. 1980; 64(12):1275-81. PMID: 7471116.
      View in: PubMed
    220. Seeger RC, Zeltzer PM, Rayner SA. Onco-neural antigen: a new neural differentiation antigen expressed by neuroblastoma, oat cell carcinoma, Wilms' tumor, and sarcoma cells. J Immunol. 1979 Apr; 122(4):1548-55. PMID: 221577.
      View in: PubMed
    221. Herschman HR, Seeger R, West G, Stahn R, Uki J. New neural cell lines derived from experimentally induced rat tumors and from human neuroblastomas. Natl Cancer Inst Monogr. 1978 May; (48):355-7. PMID: 34797.
      View in: PubMed
    222. Akeson R, Seeger RC. Interspecies neural membrane antigens on cultured human and murine neuroblastoma cells. J Immunol. 1977 Jun; 118(6):1995-2003. PMID: 68077.
      View in: PubMed
    223. West GJ, Uki J, Herschman HR, Seeger RC. Adrenergic, cholinergic, and inactive human neuroblastoma cell lines with the action-potential Na+ ionophore. Cancer Res. 1977 May; 37(5):1372-6. PMID: 15722.
      View in: PubMed
    224. Seeger RC, Rayner SA, Banerjee A, Chung H, Laug WE, Neustein HB, Benedict WF. Morphology, growth, chromosomal pattern and fibrinolytic activity of two new human neuroblastoma cell lines. Cancer Res. 1977 May; 37(5):1364-71. PMID: 856461.
      View in: PubMed
    225. Chung HS, Higgins GR, Siegel SE, Seeger RC. Abnormalities of the immune system in children with neuroblastoma related to the neoplasm and chemotherapy. J Pediatr. 1977 Apr; 90(4):548-54. PMID: 320298.
      View in: PubMed
    226. Rosenblatt J, Zeltzer PM, Portaro J, Seeger RC. Inhibition of antibody-dependent cellular cytotoxicity by protein A from Staphylococcus aureus. J Immunol. 1977 Mar; 118(3):981-5. PMID: 300395.
      View in: PubMed
    227. Zeltzer PM, Seeger RC. Microassay using radioiodinated protein A from Staphylococcus aureus for antibodies bound to cell surface antigens of adherent tumor cells. J Immunol Methods. 1977; 17(1-2):163-75. PMID: 903615.
      View in: PubMed
    228. Bloom ET, Seeger RC. Disease and non-disease-related cell-mediated cytotoxicity in humans. Cancer Res. 1976 Apr; 36(4):1361-6. PMID: 1260761.
      View in: PubMed
    229. Seeger RC, Owen JJ. Anti-tumour cytotoxic effects mediated by minor and major cell populations of lymph nodes. Nature. 1974 Nov 29; 252(5482):420-1. PMID: 4547827.
      View in: PubMed
    230. Seeger RC, Rayner SA, Owen JJ. An analysis of variables affecting the measurement of tumor immunity in vitro with 125I-iododeoxyuridine-labelled target cells. Studies of immunity to primary Moloney sarcomas. Int J Cancer. 1974 May 15; 13(5):697-713. PMID: 4367342.
      View in: PubMed
    231. Owen JJ, Seeger RC. Immunity to tumours of the murine leukaemia-sarcoma virus complex. Br J Cancer Suppl. 1973 Aug; 1:26-34. PMID: 4374230.
      View in: PubMed
    232. Seeger R, Lehmann D. [Antitumor activity of phallolysin from Amanita phalloides (author's transl)]. Naunyn Schmiedebergs Arch Pharmacol. 1973; 279(3):235-42. PMID: 4270744.
      View in: PubMed
    233. Seeger RC, Oppenheim JJ. Macrophage-bound antigens. II. Comparison of the immunogenicity of antigens bound to macrophages, lymphocytes, thymocytes and hepatoma cells. J Immunol. 1972 Aug; 109(2):255-61. PMID: 4340083.
      View in: PubMed
    234. Seeger RC, Oppenheim JJ. Macrophage-bound antigens. I. Induction of delayed hypersensitivity and priming for production of serum antibodies in guinea pigs. J Immunol. 1972 Aug; 109(2):244-54. PMID: 5047370.
      View in: PubMed
    235. Seeger RC, Oppenheim JJ. Synergistic interaction of macrophages and lymphocytes in antigen-induced transformation of lymphocytes. J Exp Med. 1970 Jul 01; 132(1):44-65. PMID: 4994445.
      View in: PubMed